Physician profile
Russell A Pecoraro
NPI 1891887394
$3,067.31
in general payments reported to CMS, 2019-2025
29 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $190 · 2021: $443 · 2022: $288 · 2023: $670 · 2024: $455 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $397.53 | 2020-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Regeneron Healthcare Solutions, INC. | $353.58 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $251.62 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $216.11 | 2022-2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $207.69 | 2021-2024 | Catalys System |
| Abbvie INC. | $168.05 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $145.08 | 2019-2021 | |
| Genentech USA, INC. | $126.43 | 2021-2025 | Vabysmo |
| Astellas Pharma US INC | $120.94 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $105.83 | 2023-2024 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Dompe US, INC. | $95.66 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $92.32 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $68.47 | 2019 | |
| Allergan, INC. | $67.24 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $56.47 | 2023-2025 | Dextenza |
| Sandoz INC. | $54.95 | 2024-2025 | Cimerli |
| Johnson & Johnson Vision Care, INC. | $48.20 | 2021 | |
| Amgen INC. | $48.06 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $47.95 | 2025 | Iluvien, Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $42.71 | 2025 | Acthar |
| Biogen, INC. | $39.92 | 2024 | Byooviz |
| Sun Pharmaceutical Industries INC. | $31.64 | 2020-2025 | |
| Horizon Therapeutics Plc | $26.72 | 2023 | Tepezza |
| Lkc Technologies, INC. | $23.44 | 2023 | |
| Harrow Eye, LLC | $21.75 | 2024 | Iheezo |
| Carl Zeiss Meditec USA, INC. | $19.61 | 2025 | |
| Kala Pharmaceuticals, INC. | $18.74 | 2022 | |
| Shire North American Group INC | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Pecoraro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.